Health systems

Cancer care is at a pivotal moment with rapid and abundant advancements. While this is promising, keeping up can be complex. Health systems work tirelessly to improve outcomes for patients while supporting those who provide their care. Exact Sciences helps that happen.

The fight against cancer is tough, but together, we’re tougher.

A health care provider seated at a conference table with colleagues having a discussion.
Enhancing care together

Health systems need a partner that understands the business they run and the service they provide. Exact Sciences equips health systems with a portfolio of tools that can amplify their impact. That means rendering cancer powerless through early detection, innovative screening solutions, and best-in-class genomic testing — at speed and at scale.

We’ll collaborate with you to help improve risk profiling, treatment plans, and patient adherence and outcomes. We'll also help address challenges that impact patient care, including clinician and staff workload, operational and workflow efficiencies, and health equity.

A group of health care staff sitting at a conference table having a discussion.

Colorectal cancer screening solutions

Boosting colorectal cancer screening rates can improve health system quality measures and patient outcomes.1,2 With the Cologuard® test, providers can engage average risk patients 45 and over in their own health with a convenient, cost-effective option that offers best-in-class detection and superior sensitivity to FIT.3 Exact Sciences has a strong history of launching screening protocols that work for everyone – and constantly applying customer feedback to help health systems advance the standard of care.

Multi-cancer early detection

Expand detection. Simplify care.

The Cancerguard™ test helps transform cancer screening by helping detect cancers without standard screening options—all through a simple blood draw. Built for seamless integration, it offers provider education and resources, and follow-up for patients with positive results, including assessment and reduction of barriers to follow-up care.

How the Cancerguard test makes a difference:

  • Helps find more cancers: Can help detect cancer types representing ≥80% of annual diagnoses in the US, including those without current recommended standard screening options.4-6
  • Helps find them earlier: Data shows potential to reduce late-stage cancer by 42%‡ and cancer-related mortality by 17%7
  • Multi-biomarker approach: The first to combine DNA methylation + protein biomarkers to expand early detection.8,9
  • High specificity: Minimizes false positives and helps reduce unnecessary imaging.4
  • Trusted innovation: Developed by Exact Sciences, makers of Cologuard®, with 20+ years in cancer diagnostics.
An Exact Sciences lab technician opening an OncoExTra test kit box.
Precision Oncology solutions

The Exact Sciences Precision Oncology portfolio doesn't stop with a test's science. It also reflects the realities of the clinical setting and what providers can face in ordering tests and delivering results to patients. Pairing comprehensive, world-class genomic tests like Oncotype DX® test with a connected digital infrastructure helps create a complete picture of each patient’s unique cancer with ease and efficiency. That frees providers and their patients to focus on what matters most — the best way forward.

We’re equipped to integrate our solutions into your workflows, streamlining your genomic cancer testing and helping you match your patients with emerging personalized treatments.

ExactNexus by Exact Sciences.

ExactNexus™ technology platform: Streamlined and secure care

Our ExactNexus technology platform helps create a unified clinical experience within the Exact Sciences ecosystem to deliver our tests and seamlessly connect health systems, providers, payers, and patients.

Footnotes and references

  1. OC FIT-CHEK, Polymedco, Inc.
  2. US data. Calculated using estimated incidence from cancers in all sites against those used in analysis (listed in the table above).
  3. Based on modeled data. Over the 10-year time horizon, the supplemental use of MCED screening reduced stage IV incidence by 876 (42%) per 100,000, relative to usual care. The 10-year reduction in cancer mortality was 439 (17%) per 100,000.

FIT Fecal Immunochemical Test

  1. Le QA, Greene M, Gohil S, et al. Adherence to multi-target stool DNA testing for colorectal cancer screening in the United States. Int J Colorectal Dis. 2025;40(1):16.
  2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2022;72(1):7-33.
  3. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
  4. Data on file. Cancerguard Test development study. 2025. Exact Sciences, Madison, WI
  5. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.
  6. Data on file. Calculated ASCEND-2 Cancer Detection and Associated Cancer Burden. 2025. Medical Affairs, Exact Sciences, Madison, WI.
  7. Chhatwal, Xiao, El Habr A, et al. The potential of multi-cancer early detection screening for reducing cancer mortality. Clin Cancer Res. 2024: 30 (21%Suppl).
  8. Gainullin V, Hwang HJ, Hogstrom L, et al. Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort. Presented at: American Association for Cancer Research Annual Meeting 2024; April 5-10, 2024; San Diego, CA. Poster LB 100. 5.
  9. Katerov SE, Fleming HL, Rugowski DE, et al. The detection of multiple cancer types with an extended set of methylation and protein markers. J Clin Oncol. 2023;41(16 suppl):3040.

Important Information about the Cologuard products


Indications for Use

The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Contraindications

The Cologuard products are not for high-risk individuals, including patients who have the following:

  • a personal history of colorectal cancer and adenomas
  • a positive result from another colorectal cancer screening method within a test recommended timeframe
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn’s disease
  • have a family history of colorectal cancer, or certain hereditary syndromes

Warnings and Precautions

All positive results should be referred to colonoscopy.

The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.

A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.

Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.

Rx only.